Jose R Arribas1, Joseph Eron. 1. Servicio de Medicina Interna, Unidad VIH Hospital La Paz, IdiPAZ. Madrid, Spain.
Abstract
PURPOSE OF REVIEW: To review recent data about advances in ART. RECENT FINDINGS: In the last 2 years, clinical trials have demonstrated the safety and efficacy of three integrase transfer inhibitors [raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG)], one new nonnucleoside reverse transcriptase inhibitor [rilpivirine (RIL)] and a new extended release formulation of nevirapine in antiretroviral-naive and experienced patients. Cobicistat (COBI), a new pharmacologic enhancer without antiretroviral activity has been studied as a booster of EVG and atazanavir (ATV). Two new single-pill fixed-dose combinations (FDCs) have been approved by regulatory agencies: RIL/tenofovir (TDF) difumarate/emtricitabine and elvitegravir/COBI/TDF difumarate/emtricitabine. A new prodrug of TDF is going to be evaluated in phase III clinical trials with the goal of showing less bone and renal toxicity. Ongoing trials are evaluating the use of nucleoside sparing regimens in antiretroviral-naive patients. Generic formulations of multiple antiretrovirals would become available in the immediate future. The efficacy and price reduction associated with generic antiretrovirals remains to be elucidated. SUMMARY: In the last 2 years, the antiretroviral armamentarium has been significantly expanded by the advent of the integrase transfer inhibitors RAL, EVG and DTG, by a new nonnucleoside reverse transcriptase inhibitor, RIL and by two new single-pill FDCs.
PURPOSE OF REVIEW: To review recent data about advances in ART. RECENT FINDINGS: In the last 2 years, clinical trials have demonstrated the safety and efficacy of three integrase transfer inhibitors [raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG)], one new nonnucleoside reverse transcriptase inhibitor [rilpivirine (RIL)] and a new extended release formulation of nevirapine in antiretroviral-naive and experienced patients. Cobicistat (COBI), a new pharmacologic enhancer without antiretroviral activity has been studied as a booster of EVG and atazanavir (ATV). Two new single-pill fixed-dose combinations (FDCs) have been approved by regulatory agencies: RIL/tenofovir (TDF) difumarate/emtricitabine and elvitegravir/COBI/TDFdifumarate/emtricitabine. A new prodrug of TDF is going to be evaluated in phase III clinical trials with the goal of showing less bone and renal toxicity. Ongoing trials are evaluating the use of nucleoside sparing regimens in antiretroviral-naive patients. Generic formulations of multiple antiretrovirals would become available in the immediate future. The efficacy and price reduction associated with generic antiretrovirals remains to be elucidated. SUMMARY: In the last 2 years, the antiretroviral armamentarium has been significantly expanded by the advent of the integrase transfer inhibitors RAL, EVG and DTG, by a new nonnucleoside reverse transcriptase inhibitor, RIL and by two new single-pill FDCs.
Authors: Hong-Tao Xu; Susan P Colby-Germinario; Peter K Quashie; Richard Bethell; Mark A Wainberg Journal: Antimicrob Agents Chemother Date: 2015-03-16 Impact factor: 5.191
Authors: Lee D Fader; Eric Malenfant; Mathieu Parisien; Rebekah Carson; François Bilodeau; Serge Landry; Marc Pesant; Christian Brochu; Sébastien Morin; Catherine Chabot; Ted Halmos; Yves Bousquet; Murray D Bailey; Stephen H Kawai; René Coulombe; Steven LaPlante; Araz Jakalian; Punit K Bhardwaj; Dominik Wernic; Patricia Schroeder; Ma'an Amad; Paul Edwards; Michel Garneau; Jianmin Duan; Michael Cordingley; Richard Bethell; Stephen W Mason; Michael Bös; Pierre Bonneau; Marc-André Poupart; Anne-Marie Faucher; Bruno Simoneau; Craig Fenwick; Christiane Yoakim; Youla Tsantrizos Journal: ACS Med Chem Lett Date: 2014-01-22 Impact factor: 4.345
Authors: Hong-Tao Xu; Susan P Colby-Germinario; Maureen Oliveira; Daniel Rajotte; Richard Bethell; Mark A Wainberg Journal: Antimicrob Agents Chemother Date: 2014-05-27 Impact factor: 5.191
Authors: Dongwei Guo; Gang Zhang; Tadeusz A Wysocki; Beata J Wysocki; Harris A Gelbard; Xin-Ming Liu; JoEllyn M McMillan; Howard E Gendelman Journal: J Virol Date: 2014-06-11 Impact factor: 5.103
Authors: Baligh R Yehia; Wanjun Cui; William W Thompson; Matthew M Zack; Lela McKnight-Eily; Elizabeth DiNenno; Charles E Rose; Michael B Blank Journal: AIDS Patient Care STDS Date: 2014-12 Impact factor: 5.078